Mineralys Therapeutics, Inc. (MLYS) Stock Statistics & Valuation Metrics

Mineralys Therapeutics, Inc. has a market cap or net worth of $2.16B. The enterprise value is $1.56B.

Mineralys Therapeutics, Inc. has 79,139,950 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mineralys Therapeutics, Inc.’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -26.38%.

The current PE Ratio of Mineralys Therapeutics, Inc. is ―. Mineralys Therapeutics, Inc.’s PEG ratio is 0.42.

In the last 12 months, Mineralys Therapeutics, Inc. had revenue of 0.00 and earned -154.65M in profits. Earnings per share was -2.29.

In the last 12 months, operating cash flow was -171.37M and capital expenditures 0.00, giving a free cash flow of -171.37M billion.

Mineralys Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Mineralys Therapeutics, Inc. upcoming earnings date is May 18, 2026, After Close (Confirmed).

Mineralys Therapeutics, Inc. as a current ratio of 43.76, with Debt / Equity ratio of 0.00%

In the past 12 months, Mineralys Therapeutics, Inc. has paid 0.00 in taxes.

Mineralys Therapeutics, Inc. EV to EBITDA ratio is -13.38, with an EV/FCF ratio of -16.02.

Mineralys Therapeutics, Inc. has $217.60M in cash and marketable securities with $0.00 in debt, giving a net cash position of $217.60M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Mineralys Therapeutics, Inc. is $53.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy